Boxer Capital, LLC Viking Therapeutics, Inc. Transaction History

Boxer Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$17.4 - $94.5 $5.22 Million - $28.4 Million	300,000 New	300,000 $24.6 Million
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $4.04 Million - $8.67 Million	500,000 Added 33.33%	2,000,000 $33.3 Million
Q4 2022 Feb 14, 2023	BUY	$2.72 - $9.4 $4.08 Million - $14.1 Million	1,500,000 New	1,500,000 $14.1 Million
Q3 2018 Nov 14, 2018	SELL	$9.7 - $19.65 $36.4 Million - $73.7 Million	-3,750,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$3.88 - $12.74 $2.19 Million - $7.19 Million	564,000 Added 17.7%	3,750,000 $35.6 Million
Q1 2018 May 15, 2018	BUY	$4.11 - $6.93 $13.1 Million - $22.1 Million	3,186,000 New	3,186,000 $13.9 Million

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $4.03B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Boxer Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Boxer Capital, LLC with notifications on news.